Ergothioneine for Parkinson's Disease
Also known as: ERGO, L-ergothioneine
ERGO's OCTN1-mediated neuronal accumulation and metal chelation may protect dopaminergic neurons from iron-catalyzed oxidative damage.
Mechanism of Action
ERGO chelates excess iron in the substantia nigra via OCTN1-mediated uptake into dopaminergic neurons. It protects against dopamine auto-oxidation, scavenges hydroxyl radicals, and may reduce α-synuclein-metal-induced aggregation.
General mechanism: Unique thiol-histidine amino acid. OCTN1-transported, mitochondrial antioxidant, metal chelator, hydroxyl radical scavenger.
Current Evidence
Reduced blood ERGO in PD patients. OCTN1 expression in substantia nigra suggests biological relevance. Mushroom consumption inversely correlated with PD risk.
Clinical Status: Biomarker data supportive. Epidemiological evidence from dietary intake.
Safety Profile
Extremely safe. Naturally present in diet (mushrooms). Dedicated OCTN1 transporter suggests biological importance. No side effects.
Key Research Questions
- Does OCTN1-mediated ERGO uptake preferentially protect dopaminergic neurons?
- Can ERGO supplementation normalize PD biomarker levels?